Piracetam

Efficacy

Dementia

A 2001 Cochrane review concluded that there was not enough evidence to support piracetam for dementia or cognitive problems. In 2008, a working group of the British Academy of Medical Sciences noted that many of the trials of piracetam for dementia were flawed.

There is insufficient evidence of piracetam as a treatment for vascular dementia.

Depression and anxiety

Some sources suggest that piracetam's overall effect on lowering depression and anxiety is higher than on improving memory. However, depression is reported to be an occasional adverse effect of piracetam.

Attention deficit hyperactivity disorder (ADHD)

Several clinical trials have looked at piracetam's efficacy as a treatment for ADHD. Many of these have found that the drug fails to deliver the same therapeutic effects as current standard treatments for the disorder. However, more than one study has found piracetam to be highly synergistic with standard ADHD therapies, accelerating and potentiating their therapeutic effects. One 2008 clinical trial found that the combination of piracetam and atomoxetine was more effective than atomoxetine alone.

While piracetam may be an effective adjuvant therapy for ADHD (when used with specific medications), there is no evidence that it is effective when used in isolation.

Other

Piracetam may facilitate the deformability of erythrocytes in capillary which is useful for cardiovascular disease.

Peripheral vascular effects of piracetam have suggested its use potential for vertigo, dyslexia, Raynaud's phenomenon and sickle cell anemia. or for fetal distress during childbirth. There is no evidence for benefit of piracetam with acute ischemic stroke, though there is debate as to its utility during stroke rehabilitation.

Anti-vasospasm

Piracetam has been found to diminish erythrocyte adhesion to vascular wall endothelium, making any vasospasm in the capillary less severe. This contributes to its efficacy in promoting microcirculation, including to the brain and kidneys.

Side effects

Symptoms including anxiety, insomnia, irritability, headache, agitation, tremor, and hyperkinesia are occasionally reported. Other reported side effects include somnolence, weight gain, clinical depression, weakness, increased libido, and hypersexuality.

According to a 2005 review, piracetam has been observed to have the following side effects: hyperkinesia, weight gain, anxiety, somnolence, depression, and weakness.

Piracetam reduces platelet aggregation as well as fibrinogen concentration, and thus is contraindicated to patients with cerebral hemorrhage.

Toxicity

The for oral consumption in humans has not been determined. For comparison, in rats the LD50 of vitamin C is 12 g/kg and the LD50 of table salt is 3 g/kg.

Mechanisms of action

Piracetam's mechanism of action, as with racetams in general, is not fully understood. The drug influences neuronal and vascular functions and influences cognitive function without acting as a sedative or stimulant. It is hypothesized to act on ion channels or ion carriers, thus leading to increased neuron excitability. GABA brain metabolism and GABA receptors are not affected by piracetam

Piracetam increases the action of the neurotransmitter acetylcholine via muscarinic cholinergic (ACh) receptors, which are implicated in memory processes. Furthermore, piracetam may have an effect on NMDA glutamate receptors, which are involved with learning and memory processes. Piracetam is thought to increase cell membrane permeability. Piracetam may exert its global effect on brain neurotransmission via modulation of ion channels (i.e., Na+, K+). Piracetam, while in the brain, appears to increase the synthesis of cytochrome b5, which is a part of the electron transport mechanism in mitochondria. But in the brain, it also increases the permeability of some intermediates of the Krebs cycle through the mitochondrial outer membrane.

Piracetam inhibits N-type calcium channels. The concentration of piracetam achieved in central nervous system after a typical dose of 1200 mg (about 100 μM) is much higher than the concentration necessary to inhibit N-type calcium channels (IC50 of piracetam in rat neurons was 3 μM).

History

Piracetam was first made some time between the 1950s and 1964 by Corneliu E. Giurgea. There are reports of it being used for epilepsy in the 1950s.

Society and culture

In 2009 piracetam was reportedly popular as a cognitive enhancement drug among students.

Legal status

Piracetam is an uncontrolled substance in the United States, meaning it is legal to possess without a license or prescription. Use of piracetam in food, supplements, medical devices, insecticides, infant formula, cosmetics, animal feed, animal drugs, tobacco products, and drugs is unlawful and constitutes an act of misbranding.

Regulatory status

In the United States, piracetam is not approved by the Food and Drug Administration. Piracetam is not permitted in compounded drugs or dietary supplements in the United States. Like most research chemicals, it has been available over-the-counter, self-regulated, and third-party lab tested by many U.S. companies for decades. Nonetheless it is still, for the purposes of U.S. law, a "New Drug" as defined by 21 U.S. Code § 321(p)(1).

In the United Kingdom, piracetam is approved as a prescription drug for adults with myoclonus of cortical origin, irrespective of cause, and should be used in combination with other anti-myoclonic therapies.

In Japan, piracetam is approved as a prescription drug.

In the Czech Republic, piracetam is available without prescription.

Piracetam has no DIN in Canada, and thus cannot be sold, but can be imported for personal use in Canada.

In Hungary, piracetam was a prescription-only medication, but as of 2020, no prescription is required and piracetam is available as an over-the-counter drug under the name Memoril Mite, and is available in 600 mg pills.

References

References

1. "Piracetam". DrugBank database.
2. [http://www.e-lactancia.org/media/papers/Piracetam-DS-UCB2013.pdf Leaflet of Piracetam].
3. (2001). "Piracetam for dementia or cognitive impairment". The Cochrane Database of Systematic Reviews.
4. (March 2020). "Presence of Piracetam in Cognitive Enhancement Dietary Supplements". JAMA Internal Medicine.
5. (2005). "Piracetam: a review of pharmacological properties and clinical uses". CNS Drug Reviews.
6. (May 2008). "Brain science, addiction and drugs". Academy of Medical Sciences.
7. (September 2017). "Pharmacotherapy for Vascular Cognitive Impairment". CNS Drugs.
8. (February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs.
9. [http://compendium.ch/mpro/mnr/3048/html/de Nootropil®]. Arzneimittel-Kompendium der Schweiz. 2013-09-12. Retrieved 2013-10-27.
10. (2023-05-11). "Is Piracetam Good for ADHD? - Epimodels".
11. (2008). "[Atomoxetine and piracetam in the treatment of attention deficit hyperactivity disorder in children]". Zhurnal Nevrologii I Psikhiatrii imeni S.S. Korsakova.
12. (June 2012). "Piracetam for fetal distress in labour". The Cochrane Database of Systematic Reviews.
13. (September 2012). "Piracetam for acute ischaemic stroke". The Cochrane Database of Systematic Reviews.
14. (July 2016). "Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials". CNS Drugs.
15. (October 2017). "Effects of Central Nervous System Drugs on Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Clinical Drug Investigation.
16. (1983). "Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment". Psychopharmacology.
17. (1978). "Piracetam in the treatment of post-concussional syndrome. A double-blind study". European Neurology.
18. "Piracetam Material Safety Sheet". Spectrum.
19. (May 1994). "Piracetam and other structurally related nootropics". Brain Research. Brain Research Reviews.
20. (January 1982). "The nootropic concept and its prospective implications". Drug Development Research.
21. (2005). "Piracetam--an old drug with novel properties?". Acta Poloniae Pharmaceutica.
22. (March 1999). "Piracetam: novelty in a unique mode of action". Pharmacopsychiatry.
23. (October 1976). "Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and methamphetamine". Biochemical Pharmacology.
24. (1986). "Piracetam: physiological disposition and mechanism of action". Advances in Neurology.
25. (July 2006). "Rapid determination of piracetam in human plasma and cerebrospinal fluid by micellar electrokinetic chromatography with sample direct injection". Journal of Chromatography A.
26. (October 2012). "A novel CaV2.2 channel inhibition by piracetam in peripheral and central neurons". Experimental Biology and Medicine.
27. (2013). "Drug Discovery: Practices, Processes, and Perspectives". John Wiley & Sons.
28. (2016). "The End of Epilepsy?: A History of the Modern Era of Epilepsy Research 1860-2010". Oxford University Press.
29. (1 October 2009). "Call for testing on 'smart drugs'". Fairfax Media.
30. "Erowid Piracetam Vault: Legal Status".
31. (26 September 2019). "FDA proposes ban on curcumin and other naturopathic favorites in compounded drugs". [[Science-Based Medicine]].
32. "Parallel import (PI) licences granted in June 2015". UK Government.
33. "Nootropil Tablets 800 mg".
34. (1999-11-25). "UCB's piracetam approved in Japan". The Pharma Letter.
35. "Fulltext".
36. "Data file for medicines?".
37. (1 June 2010). "Guidance Document on the Import Requirements for Health Products under the Food and Drugs Act and its Regulations (GUI-0084)". Health Canada / Health Products and Food Branch Inspectorate.